Observed maximum plasma concentration (Cmax) assessment for abediterol on Day 1;Time to reach maximum plasma concentration (tmax) assessment for abediterol on Day 1;Area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUClast) assessment for abediterol on Day 1;Area under the plasma concentration-curve from time zero to 24 hours post-dose (AUC(0-24)) assessment for abediterol on Day 1;Observed maximum concentration (Cmax) assessment for abediterol on Day 9;Time to reach maximum concentration (tmax) assessment for abediterol on Day 9;Terminal rate constant, estimated by log-linear LS regression of the terminal part of the concentration-time curve (?z) assessment for abediterol on Day 9;Terminal half-life, estimated as (ln2)/?z (t½?z) assessment for abediterol on Day 9;Area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUClast) assessment for abediterol on Day 9;Area under the plasma concentration-curve from time zero to 24 hours post-dose (AUC(0-24)) assessment for abediterol on Day 9;Apparent clearance for drug estimated as dose divided by AUC0-24 (CL/F) assessment for abediterol on Day 9;Average plasma concentration during a dosing interval, estimated as AUC0-24/24 (Cavg) assessment for abediterol on Day 9;Fluctuation index during a dosing interval estimated as 100*(Cmax - Cmin)/Cavg (%), where Cmin is the minimum concentration at the end of the dosing interval (%Fluctuation) assessment for abediterol on Day 9;Accumulation ratio for Cmax estimated as (Cmax on Day 9/Cmax on Day 1) (Rac (Cmax)) assessment for abediterol on Day 9;Accumulation ratio for AUC0-24 estimated as (AUC0-24 on Day 9/AUC0-24 on Day 1) (Rac (AUC0-24)) assessment for abediterol on Day 9;Vital sign (Blood pressure [BP]);Vital sign (pulse);12-lead Electrocardiograms (ECGs) including high precision QTc analysis and telemetry;Clinical laboratory assessments (hematology, clinical chemistry and urinalysis);Number of patients with Adverse Events (AEs);Observed maximum plasma concentration (Cmax) assessment for abediterol on Day 1;Time to reach maximum plasma concentration (tmax) assessment for abediterol on Day 1;Area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUClast) assessment for abediterol on Day 1;Area under the plasma concentration-curve from time zero to 24 hours post-dose (AUC(0-24)) assessment for abediterol on Day 1;Observed maximum concentration (Cmax) assessment for abediterol on Day 9;Time to reach maximum concentration (tmax) assessment for abediterol on Day 9;Terminal rate constant, estimated by log-linear LS regression of the terminal part of the concentration-time curve (?z) assessment for abediterol on Day 9;Terminal half-life, estimated as (ln2)/?z (t½?z) assessment for abediterol on Day 9;Area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUClast) assessment for abediterol on Day 9;Area under the plasma concentration-curve from time zero to 24 hours post-dose (AUC(0-24)) assessment for abediterol on Day 9;Apparent clearance for drug estimated as dose divided by AUC0-24 (CL/F) assessment for abediterol on Day 9;Average plasma concentration during a dosing interval, estimated as AUC0-24/24 (Cavg) assessment for abediterol on Day 9;Fluctuation index during a dosing interval estimated as 100*(Cmax - Cmin)/Cavg (%), where Cmin is the minimum concentration at the end of the dosing interval (%Fluctuation) assessment for abediterol on Day 9;Accumulation ratio for Cmax estimated as (Cmax on Day 9/Cmax on Day 1) (Rac (Cmax)) assessment for abediterol on Day 9;Accumulation ratio for AUC0-24 estimated as (AUC0-24 on Day 9/AUC0-24 on Day 1) (Rac (AUC0-24)) assessment for abediterol on Day 9;Vital sign (Blood pressure [BP]);Vital sign (pulse);12-lead Electrocardiograms (ECGs) including high precision QTc analysis and telemetry;Clinical laboratory assessments (hematology, clinical chemistry and urinalysis);Number of patients with Adverse Events (AEs);Observed maximum plasma concentration (Cmax) assessment for abediterol on Day 1;Time to reach maximum plasma concentration (tmax) assessment for abediterol on Day 1;Area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUClast) assessment for abediterol on Day 1;Area under the plasma concentration-curve from time zero to 24 hours post-dose (AUC(0-24)) assessment for abediterol on Day 1;Observed maximum concentration (Cmax) assessment for abediterol on Day 9;Time to reach maximum concentration (tmax) assessment for abediterol on Day 9;Terminal rate constant, estimated by log-linear LS regression of the terminal part of the concentration-time curve (?z) assessment for abediterol on Day 9;Terminal half-life, estimated as (ln2)/?z (t½?z) assessment for abediterol on Day 9;Area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUClast) assessment for abediterol on Day 9;Area under the plasma concentration-curve from time zero to 24 hours post-dose (AUC(0-24)) assessment for abediterol on Day 9;Apparent clearance for drug estimated as dose divided by AUC0-24 (CL/F) assessment for abediterol on Day 9;Average plasma concentration during a dosing interval, estimated as AUC0-24/24 (Cavg) assessment for abediterol on Day 9;Fluctuation index during a dosing interval estimated as 100*(Cmax - Cmin)/Cavg (%), where Cmin is the minimum concentration at the end of the dosing interval (%Fluctuation) assessment for abediterol on Day 9;Accumulation ratio for Cmax estimated as (Cmax on Day 9/Cmax on Day 1) (Rac (Cmax)) assessment for abediterol on Day 9;Accumulation ratio for AUC0-24 estimated as (AUC0-24 on Day 9/AUC0-24 on Day 1) (Rac (AUC0-24)) assessment for abediterol on Day 9;Vital sign (Blood pressure [BP]);Vital sign (pulse);12-lead Electrocardiograms (ECGs) including high precision QTc analysis and telemetry;Clinical laboratory assessments (hematology, clinical chemistry and urinalysis);Number of patients with Adverse Events (AEs)